**Supplementary Table S4.** Stratification of 48-week HBV DNA levels in subgroup with baseline HBV-DNA ≥8 log10 IU/mL and HBeAg-positive subgroup

|  |  |  |  |
| --- | --- | --- | --- |
| Subgroup | TMF group | Blank control group | P |
| No. of patients with baseline HBV-DNA ≥8 log10 IU/mL | 21 | 14 |  |
| HBV DNA at week 48 |  |  | <0.001 |
|  <20 IU/mL, n (%) | 1 (4.8) | 0 |  |
|  20-2000 IU/mL, n (%) | 18 (85.7) | 0 |  |
|  >2000 IU/mL, n (%) | 2 (9.5) | 14 (100.0) |  |
| No. of patients with baseline positive HBeAg  | 23 | 25 |  |
| HBV DNA at week 48 |  |  | <0.001 |
|  <20 IU/mL, n (%) | 2 (8.7) | 0 |  |
|  20-2000 IU/mL, n (%) | 19 (82.6) | 1 (4.0) |  |
|  >2000 IU/mL, n (%) | 2 (8.7) | 24 (96.0) |  |

TMF: tenofovir amibufenamide; HBeAg: hepatitis B e-antigen; HBV-DNA: hepatitis B virus DNA.